4-cyanophenylalanine methyl ester | 272784-76-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-cyanophenylalanine methyl ester
• 英文别名: (S)-methyl 2-amino-3-(4-cyanophenyl)propanoate；methyl (S)-2-amino-3-(4-cyanophenyl)propanoate；L-4'-Cyanophenylalanine methyl ester；methyl (2S)-2-amino-3-(4-cyanophenyl)propanoate
• CAS: 272784-76-6
• 化学式: C₁₁H₁₂N₂O₂
• 分子量: 204.228
• InChiKey: YQFIQNIOQYPOTP-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-cyanophenylalanine methyl ester 在 palladium on activated charcoal 盐酸 、 4-二甲氨基吡啶 、 lithium hydroxide 、 4-nitrophenyl carbonate-Wang resin 、 TEA 、 四丁基氟化铵 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 甲醇 、 乙腈 为溶剂， 生成 (S)-3-(4-Aminomethyl-phenyl)-N,N-dimethyl-2-(naphthalene-2-sulfonylamino)-propionamide
  参考文献：
  名称：

  Solid phase synthesis of benzylamine-derived sulfonamide library

  摘要：

  Using solid phase synthesis, a library has been constructed of benzylamine-derived sulfonamides which have strong inhibitory activity against the blood coagulant thrombin. The library compounds were obtained in good yield and high purity; four of these thrombin inhibitors showed nanomolar potency (Ki 600-10 nM). (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00114-0
• 作为产物：
  描述：

  (S)-甲基2-((叔-丁氧羰基)氨基)-3-(4-氰基苯基)丙酯 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 4-cyanophenylalanine methyl ester
  参考文献：
  名称：

  Solid phase synthesis of benzylamine-derived sulfonamide library

  摘要：

  Using solid phase synthesis, a library has been constructed of benzylamine-derived sulfonamides which have strong inhibitory activity against the blood coagulant thrombin. The library compounds were obtained in good yield and high purity; four of these thrombin inhibitors showed nanomolar potency (Ki 600-10 nM). (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00114-0

文献信息

• [EN] GLP-1 RECEPTOR MODULATORS<br/>[FR] NOUVEAUX MODULATEURS DU RÉCEPTEUR DU GLP-1
  申请人：CELGENE INTERNAT II SARL

  公开号：WO2016094729A1

  公开（公告）日：2016-06-16

  Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where "^^^^" represents either or both the R and S form of the compound) (I) where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.

  提供了一些化合物，这些化合物可以调节胰高血糖素样肽1（GLP-1）受体，以及它们的合成方法，以及它们的治疗和/或预防使用方法。这类化合物可以单独作为GLP-1受体的调节剂或增强剂，或者与肠促胰岛素肽（如GLP-1(7-36)和GLP-1(9-36)）一起使用，或者与基于肽的治疗方法（如艾塞那肽和利拉鲁肽）一起使用，并具有以下一般结构（其中"^^^^"代表化合物的R和S形式中的一个或两个）(I) 其中A、B、C、Y1、Y2、Z、R1、R2、R3、R4、R5、W1、n、p和q的定义如下。
• [EN] NOVEL GLP-1 RECEPTOR MODULATORS<br/>[FR] NOUVEAUX MODULATEURS DU RÉCEPTEUR GLP-1
  申请人：RECEPTOS INC

  公开号：WO2014201172A1

  公开（公告）日：2014-12-18

  Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where "(Ⅰ)" represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.

  提供了一些化合物，这些化合物可以调节胰高血糖素样肽1（GLP-1）受体，以及它们的合成方法和治疗性及/或预防性使用方法。这些化合物可以单独作为GLP-1受体的调节剂或增强剂，或者与肠促胰岛素肽（如GLP-1(7-36)和GLP-1(9-36)）一起使用，或者与基于肽的治疗方法（如艾塞那肽和利拉鲁肽）一起使用，并具有以下一般结构（其中"(Ⅰ)"代表化合物的R和S形式中的一个或两个）：其中A、B、C、Y1、Y2、Z、R1、R2、R3、R4、R5、W1、n、p和q如本文所述定义。
• NOVEL HYDROXAMIC ACID DERIVATIVES
  申请人：Daiichi Fine Chemical Co., Ltd.

  公开号：EP1179529A1

  公开（公告）日：2002-02-13

  Disclosed are compounds which have not only potent metalloproteinase-inhibiting activity but also amazingly excellent bioavailability and biological activity in vivo, including the property of being well absorbed via oral routes, thereby serving as useful pharmaceuticals, intermediates and processes for the production thereof. The disclosed compounds of the formula (I): wherein R1 is hydrogen, or a hydroxy-protecting group; R2 is hydrogen, or an amino-protecting group; R3, R7, and R8, which may be identical or different, are each independently hydrogen, hydroxy, unsubstituted or optionally substituted (C1-C6) alkyl, or unsubstituted or optionally substituted aryl-(C1-C6) alkyl; R4 is unsubstituted or optionally substituted (C1-C6) alkyl, or unsubstituted or optionally substituted aryl-(C1-C6) alkyl; R5 is hydrogen, unsubstituted or optionally substituted alkyl, unsubstituted or optionally substituted aralkyl, or a carboxy-protecting group; R6 is hydrogen, hydroxy, amino, and a group of the formula: -X-Y wherein X is oxygen, (C1-C6) alkylene or phenylene, Y is a group of the formula: -A-B or -B, wherein A is (C1-C6) alkylene, imino, and (C1-C6) alkyleneimino, and B is hydrogen, amino, amidino, sulfonyl, acylimidoyl, unsubstituted or optionally substituted imidazolyl, unprotected or optionally protected bis(phosphono)methyl or unprotected or optionally protected bis(phosphono)hydroxymethyl; or salts thereof are useful for pharmaceutical and/or veterinary compositions, particularly as metalloproteinase inhibitors which inhibit matrix metalloproteinases or tumor necrosis factor-α-converting enzymes (TNF-α convertases).

  本公开的化合物不仅具有强大的金属蛋白酶抑制活性，而且在体内具有出色的生物利用度和生物活性，包括经口途径吸收良好的特性，因此可用作有用的药物、中间体和生产过程。公开的化合物的结构式（I）如下：其中R1是氢或羟基保护基；R2是氢或氨基保护基；R3、R7和R8可以相同也可以不同，分别独立地是氢、羟基、未取代或可选择取代的（C1-C6）烷基，或未取代或可选择取代的芳基-（C1-C6）烷基；R4是未取代或可选择取代的（C1-C6）烷基，或未取代或可选择取代的芳基-（C1-C6）烷基；R5是氢、未取代或可选择取代的烷基、未取代或可选择取代的芳基烷基，或羧基保护基；R6是氢、羟基、氨基，以及下式的基团：-X-Y，其中X是氧、（C1-C6）烷基或苯基，Y是下式的基团：-A-B或-B，其中A是（C1-C6）烷基、亚胺基和（C1-C6）烷基亚胺基，B是氢、氨基、酰胺基、磺酰基、乙酰亚胺基，未取代或可选择取代的咪唑基，未保护或可选择保护的双（膦酸甲基）或未保护或可选择保护的双（膦酸羟甲基）；或其盐在制药和/或兽医组合物中具有用途，尤其作为抑制基质金属蛋白酶或肿瘤坏死因子-α转化酶（TNF-α转化酶）的金属蛋白酶抑制剂。
• [EN] MODULATORS OF C3A RECEPTORS<br/>[FR] MODULATEURS DES RÉCEPTEURS C3A
  申请人：UNIV QUEENSLAND

  公开号：WO2013067578A1

  公开（公告）日：2013-05-16

  Heterocyclic compounds that modulate C3a receptors and their use in the treatment or prevention of inflammatory diseases, infectious diseases, cancers, metabolic disorders, obesity, type 2 diabetes, metabolic syndrome and associated cardiovascular diseases are described. The use of the compounds in stimulating or suppressing an immune response is also described together with pharmaceutical compositions comprising the compounds or their pharmaceutically acceptable salts.

  描述了调节C3a受体的杂环化合物及其在治疗或预防炎症性疾病、传染病、癌症、代谢紊乱、肥胖、2型糖尿病、代谢综合征以及相关心血管疾病中的用途。还描述了这些化合物在刺激或抑制免疫反应中的用途，以及包含这些化合物或其药用可接受盐的制药组合物。
• [EN] TRIAZINE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE TRIAZINE ET LEURS UTILISATIONS
  申请人：ADURO BIOTECH INC

  公开号：WO2019245910A1

  公开（公告）日：2019-12-26

  The present invention relates to triazine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

  本发明涉及三嗪化合物。本发明还涉及含有这些化合物的药物组合物以及通过向需要的受试者施用这些化合物和药物组合物来治疗自身免疫、炎症和神经退行性疾病的方法。本发明还涉及利用这些化合物进行研究或其他非治疗目的的用途。